Legal & General Group Plc acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 109,870 shares of the company's stock, valued at approximately $5,194,000. Legal & General Group Plc owned about 0.23% of Prestige Consumer Healthcare at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock valued at $2,558,000 after acquiring an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Prestige Consumer Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock worth $2,535,000 after purchasing an additional 1,289 shares during the period. Goldman Sachs Group Inc. raised its holdings in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Jane Street Group LLC lifted its position in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock valued at $9,010,000 after purchasing an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on PBH. Weiss Ratings cut shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, June 25th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a report on Thursday, May 14th. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating on the stock in a research note on Friday, May 15th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a report on Monday, August 10th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $70.75.
Check Out Our Latest Stock Report on PBH
Prestige Consumer Healthcare Price Performance
Prestige Consumer Healthcare stock opened at $52.63 on Friday. The firm has a market capitalization of $2.49 billion, a P/E ratio of 14.74, a PEG ratio of 1.66 and a beta of 0.33. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The business has a 50-day moving average of $50.70 and a 200-day moving average of $54.15. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. During the same period last year, the company posted $0.90 EPS. Prestige Consumer Healthcare's revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current year.
Prestige Consumer Healthcare Company Profile
(
Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.
Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
